MOUNTAINEER Study: An Effective Treatment Combination For Metastatic Colorectal Cancer

By Oncology Brothers - Last Updated: March 1, 2023

In this podcast episode, the Oncology Brothers (Drs. Rohit & Rahul Gosain) are joined by Dr. Tanios Bekaii-Saab, Mayo Clinic Comprehensive Cancer Center, to discuss the MOUNTAINEER Phase II study, which prompted the FDA approval of tucatinib in combination with trastuzumab in treating advanced colorectal cancer HER2 positive patients.

10-Year KEYNOTE-016: Pembrolizumab Durable in MSI-H/dMMR Tumors

Lauren Dembeck, PhDColorectal Cancer | May 29, 2025

Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.

CodeBreaK 101 Update Sheds Light on OS and PFS Data on Sotorasib Plus Panitumumab and FOLFIRI Combo for Mutated Colorectal Cancer

Emily MenendezColorectal Cancer | May 28, 2025

Sotorasib with panitumumab and FOLFIRI has shown promising long-term efficacy results in pretreated KRAS G12C–mutated ...

Top 3 Liver-Directed Therapies for Colorectal Cancer Metastases

Christopher Lieu, MDLiver Cancer | May 16, 2025

Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.

Top 3 Precision Targets for Metastatic Colorectal Cancer

Christopher Lieu, MDColorectal Cancer | May 16, 2025

Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.

DYNAMIC Study 5-Year Outcomes Provide OS and ctDNA Insight

Emily MenendezColorectal Cancer | May 9, 2025

The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.

MOUNTAINEER Study: An Effective Treatment Combination For Metastatic Colorectal Cancer

Related Posts